Os glicocorticoides e seus efeitos no crescimento e na mineralização óssea
Donatti, Teresinha Lermen; Koch, Vera Hermina Kalika; Takayama, Liliam; Pereira, Rosa Maria Rodrigues.
J. pediatr. (Rio J.)
; 87(1): 4-12, jan.-fev. 2011.
Artigo em Português | LILACS | ID: lil-576122
Documentos relacionados
[Exploration and prospect of the whole course management model of osteoporosis].
Implementation and operationalization of Integrated People-Centred Health Services delivery strategies in integrated osteoporosis care (IOC) initiatives: a systematic review.
WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects.
[Secondary osteoporosis. Glucocorticoid excess-related osteoporosis.]
High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
Exploring epigenetic strategies for the treatment of osteoporosis.
Extracellular Vesicles in Bone Remodeling and Osteoporosis.
THE EFFECTS OF HYPONATREMIA ON BONE DENSITY AND FRACTURES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.
When and how to stop denosumab therapy in a patient with osteoporosis.